Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ronald J. Bosch, Ph.D.

Co-Author

This page shows the publications co-authored by Ronald Bosch and Rajesh Gandhi.
Connection Strength

2.915
  1. Associations between multiple measures of HIV-1 persistence on suppressive antiretroviral therapy. J Infect Dis. 2022 Feb 04.
    View in: PubMed
    Score: 0.246
  2. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. J Infect Dis. 2021 02 03; 223(2):225-233.
    View in: PubMed
    Score: 0.230
  3. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog. 2017 Apr; 13(4):e1006285.
    View in: PubMed
    Score: 0.177
  4. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016 Jan 28; 30(3):343-53.
    View in: PubMed
    Score: 0.162
  5. HLA Class I Alleles Associated with Mortality in Thai Military Recruits with HIV-1 CRF01_AE Infection. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):44-9.
    View in: PubMed
    Score: 0.158
  6. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Oct 01; 67(2):153-60.
    View in: PubMed
    Score: 0.148
  7. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr. 2013 May 01; 63(1):101-4.
    View in: PubMed
    Score: 0.134
  8. Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther. 2013; 18(4):607-13.
    View in: PubMed
    Score: 0.132
  9. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Mar 01; 59(3):229-35.
    View in: PubMed
    Score: 0.124
  10. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010 Aug 10; 7(8).
    View in: PubMed
    Score: 0.111
  11. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis. 2010 Jan 15; 201(2):293-6.
    View in: PubMed
    Score: 0.107
  12. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 2009 Oct 09; 27(43):6088-94.
    View in: PubMed
    Score: 0.102
  13. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2022 03 09; 74(5):865-870.
    View in: PubMed
    Score: 0.062
  14. Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial). Clin Infect Dis. 2022 Feb 17.
    View in: PubMed
    Score: 0.062
  15. Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. Front Cell Infect Microbiol. 2022; 12:757846.
    View in: PubMed
    Score: 0.062
  16. Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. AIDS. 2021 11 01; 35(13):2225-2227.
    View in: PubMed
    Score: 0.060
  17. Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy. J Infect Dis. 2021 02 13; 223(3):462-470.
    View in: PubMed
    Score: 0.058
  18. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight. 2021 02 08; 6(3).
    View in: PubMed
    Score: 0.057
  19. T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS. 2020 01 01; 34(1):15-24.
    View in: PubMed
    Score: 0.053
  20. Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men. AIDS. 2019 11 15; 33(14):2149-2156.
    View in: PubMed
    Score: 0.053
  21. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):e27-e31.
    View in: PubMed
    Score: 0.052
  22. Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):594-599.
    View in: PubMed
    Score: 0.052
  23. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. J Clin Invest. 2019 07 15; 129(8):3339-3346.
    View in: PubMed
    Score: 0.052
  24. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
    View in: PubMed
    Score: 0.049
  25. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.
    View in: PubMed
    Score: 0.048
  26. Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis. 2018 06 20; 218(2):234-238.
    View in: PubMed
    Score: 0.048
  27. Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun. 2017; 2(3):431-445.
    View in: PubMed
    Score: 0.046
  28. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathog. 2017 Sep; 13(9):e1006629.
    View in: PubMed
    Score: 0.045
  29. Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr. 2016 07 01; 72(3):310-3.
    View in: PubMed
    Score: 0.042
  30. Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis. 2016 Feb 15; 213(4):556-60.
    View in: PubMed
    Score: 0.039
  31. Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir. Open Forum Infect Dis. 2015 Apr; 2(2):ofv045.
    View in: PubMed
    Score: 0.038
  32. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis. 2014 Nov 01; 59(9):1312-21.
    View in: PubMed
    Score: 0.037
  33. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15; 210(10):1549-54.
    View in: PubMed
    Score: 0.036
  34. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther. 2013; 18(1):39-43.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.